Cost analysis of three different surgical procedures for treatment of a pelvic tumour

Objective: This exploratory study aimed to evaluate and compare the treatment costs of taxane-based versus cisplatin-based chemotherapy.Methods: This study used data from the medical and financial records of ovarian cancer patients who were admitted to Dharmais NationalCancer Hospital (RSKD) between 2008 and 2012 and subsequently underwent surgery and were treated with chemotherapy. Data were analyzedusing descriptive analysis, and a Kaplan–Meier graph was plotted to compare the survival of the patients in the taxane-based and cisplatin-basedchemotherapy groups.Results: Of 41 patients, treatment costs were available for nine patients who had undergone taxane-based chemotherapy and for 31 patients who hadundergone cisplatin-based chemotherapy. In general, surgical procedures accounted for the highest proportion of the treatment costs, followed bychemotherapy. Taxane-based chemotherapy (six cycles) was 4 times more expensive than cisplatin-based therapy. The pre- and post-chemotherapycosts of care among those treated with the taxane-based regimen were 3-4 times more expensive than those of the patients who received cisplatinbasedtreatment. The disease-free recurrence duration of the patients treated with taxane was longer (median=18 months) than that of the patientstreated with cisplatin (median=5 months).Conclusions: Taxane-based therapy increased the disease-free recurrence duration of the patients, with disease-free recurrence 3 times longer thanthat of the patients treated with the cisplatin-based regimen. However, the treatment costs of the taxane-based regimen were 4 times higher thanthose of the cisplatin-based treatment.

Download Full-text

Are Office-Based Oral and Maxillofacial Surgical Procedures Profitable? A Benefit–Cost Analysis

Journal of Oral and Maxillofacial Surgery ◽

10.1016/j.joms.2019.05.015 ◽

2019 ◽

Vol 77 (11) ◽

pp. 2205-2214

Author(s):

Jason P. Jones ◽

Edward Ellis

Keyword(s):

Cost Analysis ◽

Surgical Procedures ◽

Benefit Cost Analysis ◽

Benefit Cost

Download Full-text

A 1-Year Cost Analysis of Spinal Surgical Procedures in Spain: Neurosurgeons Versus Orthopedic Surgeons

Neurospine ◽

10.14245/ns.1836170.085 ◽

2019 ◽

Vol 16 (2) ◽

pp. 354-359 ◽

Cited By ~ 1

Author(s):

Martín Avellanal ◽

Mónica Martin-Corvillo ◽

Laura Barrigon ◽

Manuel Vazquez Espi ◽

Clara M. Esteban Escolar

Keyword(s):

Cost Analysis ◽

Surgical Procedures ◽

Orthopedic Surgeons

Download Full-text

Single visit surgery for pediatric ambulatory surgical procedures: a satisfaction and cost analysis

Journal of Pediatric Surgery ◽

10.1016/j.jpedsurg.2017.10.021 ◽

2018 ◽

Vol 53 (1) ◽

pp. 81-85 ◽

Cited By ~ 1

Author(s):

Jacob K. Olson ◽

Lisa A. Deming ◽

Denis R. King ◽

Terrence M. Rager ◽

Sarah Gartner ◽

...

Keyword(s):

Cost Analysis ◽

Surgical Procedures ◽

Ambulatory Surgical Procedures ◽

Single Visit

Download Full-text

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib

Lung Cancer Management ◽

10.2217/lmt-2019-0011 ◽

2020 ◽

Vol 9 (1) ◽

pp. LMT28

Author(s):

Dolores Isla ◽

Bartomeu Massuti ◽

Martín Lázaro ◽

Lucía Ruiz de Alda ◽

Rocio Gordo ◽

...

Keyword(s):

Brain Metastasis ◽

Brain Metastases ◽

Cost Analysis ◽

Surgical Procedures ◽

Laboratory Tests ◽

Imaging Techniques ◽

Diagnostic Laboratory ◽

Medical Visits ◽

Results Management ◽

Diagnostic Laboratory Tests

Aim: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib. Methods: Management cost/year (€ 2018) in patients with and without BM was estimated with disaggregated resource consumption provided by local oncologists, including medical visits, hospitalizations, diagnostic/laboratory tests, imaging techniques and surgical procedures. The comparison of costs/year with alectinib and crizotinib, considered the cumulative 12-month incidence of BM in ALEX trial (9.4 and 41.4%, respectively). Results: Management cost was €6173.42/patient-year without BM and €21,637.50/patient-year with BM. With alectinib, average cost/patient was lower than crizotinib (€4948.51/patient-year) Conclusion: Prevention of BM with alectinib may result in reductions of cost/year in the management of advanced ALK+ NSCLC.

Download Full-text